AI Medical Technology Company AIRS Medical Secures $20 Million in Series C Funding
AI medical technology company, AIRS Medical, known for its pioneering work in artificial intelligence and robotics for healthcare applications, has successfully completed its Series C funding round, raising $20 million from seven institutional investors based in Korea. The funding will be utilized to support the companys flagship product, SwiftMR™, and further advance its mission of transforming preventive healthcare through technological innovation.
Leading the funding round were BSK Investment and Shinyoung Securities, indicating a strong show of confidence in AIRS Medicals cuttingedge AI solutions and their potential to revolutionize the healthcare industry. The investment will enable AIRS Medical to enhance patient outcomes by proactively detecting diseases, reducing costs, and improving accessibility to MRI scans for patients with conditions such as dementia, stroke, and cancer.
The successful funding round signifies the companys commitment to expanding access to quality preventive care globally. Since the launch of SwiftMR™ in 2021, AIRS Medical has made significant strides, entering markets in the United States and Europe, which now contribute over half of the companys annual recurring revenue (ARR).
Hyeseong Lee, CEO of AIRS Medical, expressed excitement about the support from investors, stating that the funding will empower the company to increase access to preventive healthcare services and create a healthier future for individuals worldwide. With a focus on accelerating growth and innovation, AIRS Medical aims to expand its presence in international markets, invest in research and development, and continue enhancing patient outcomes on a global scale.
